Roshmere

Roshmere is a clinical-stage biotechnology company dedicated to the development of novel therapeutics for chronic kidney disease (CKD) and associated complications. The company's primary focus is on addressing iron deficiency anemia (IDA), a common and debilitating condition in CKD patients, through its lead candidate ROS-101. ROS-101 is an oral iron therapy engineered to provide superior absorption and gastrointestinal tolerability compared to current standard-of-care oral irons. Led by a management team with deep expertise in the renal and iron deficiency markets, Roshmere is positioned to advance its pipeline through clinical validation. The company operates as a private entity, supported by investors specializing in life sciences and nephrology.